Skip to main content
Equibles

CLGN · CollPlant Biotechnologies Ltd

Track CLGN — free

Use CLGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CLGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.56 +0.40 (+9.62%) At close · Sep 18
Rebalance outlook locked
Market Cap
$6.60M
Shares
1.89M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.56 Open$4.15 Day$4.11–4.78 52W close$2.73–31.40 Avg vol 30d730K Short int13K · 0.7% float · 1.0d Short vol29% Last earningsSep 30, 2024 DataJan 2020–Sep 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-28.1%
Year over year
Operating margin
-484.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.7%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −35%
below
Price vs 50-day avg +37%
above
RSI (14) 71
overbought
MACD trend Positive
52-week position 6%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +43%
trailing
6-month return −27%
trailing
YTD return −67%
this year
Relative strength −47%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $3 › 200d $7 — 200d above 50d
Institutional flow Distributing
-25% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.69% of float · ▲ +498.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
15 holders — mid 3-yr range
Squeeze score 55
elevated · 0–100
Fundamentals
Excellent
Revenue growth +360%
Y/Y
Gross margin 65%
expanding
EPS growth +35%
Y/Y
Free cash flow $-9.4M
Balance sheet $13.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 113%
annualized · 1-yr
Max drawdown −91%
past year
ATR 13.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−35% Bearish
Price vs 50-day avg
+37% Bullish
RSI (14)
71 Bearish
MACD trend
Positive Bullish
52-week position
6% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $7 — 200d above 50d
Institutional flow Distributing
-25% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.69% of float · ▲ +498.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
15 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $5 · 6% Range high $31
vs 200-day avg -35% vs 50-day avg +37%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CLGN
CollPlant Biotechnologies Ltd
this stock
$6.60M — +360.4% — 0.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.06B +12.1% +46.2% 29.9 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.80B +1.7% +20.8% 19.4 2.5%
MRNA
Moderna, Inc.
 $61.50B +422.3% +4.3% — 9.8%
ARGX
Argenx SE
 $60.93B +17.8% — — 2.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
15
% held
8.8%
Net QoQ
+14.2K sh
Top holder
PINNACLE ASSOCIATES LTD
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
13.1K
Days to cover
1.0d
Change
+10.9K sh
View
Short Volume
Short vol %
29%
As of
Sep 18, 2026
Short Total
View
Fails to Deliver
FTD shares
45.4K
Value
$16.3K
As of
Aug 31, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Aug 10, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.4M
Net income (FY)
$-11.5M
EPS diluted
$-9.40
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 18, 2026
This year
21
View
Proposed Sales
Value
$308.0K
Shares
140.0K
Filed
Oct 9, 2025
View
Exempt Offerings
Offering
$10.4M
Filed
Jul 20, 2026
View
Earnings & Events
Earnings Calls
Last call
Sep 30, 2024
View

Performance

5D 20D 120D MTD YTD
CLGN +30.3% +43.4% -26.9% +17.5% -67.4%
SPY -0.3% -0.1% +20.1% -0.7% +11.7%
vs SPY +30.6% +43.5% -47.0% +18.2% -79.1%
Key facts CIK 1631487 CUSIP M2R51X116 13F (30d) 1 filings 1 filers Visit website Investor relations